Navigation Links
Testosterone replacement theraphy beneficial in men 60 and older
Date:4/7/2008

SAN DIEGO, CA The risk of osteoporosis (bone fracture) in women is highly recognized by the public. Less appreciated is the fact that the disorder also occurs in men. Some two million males have been diagnosed with osteoporosis and another three million are at risk.

Gender-based hormones and age are thought to be major factors behind bone fractures in both sexes. Women with low levels of estrogen and men with low levels of the testosterone are known to be at risk. Low levels of gender hormones can lead to diminished bone mineral density (BMD; also known as bone mass). Reduced bone density or bone mass means there is less cushioning to protect the bone from cracking in a slip or fall.

For this reason, testosterone replacement therapy (TRT) is the standard of care used to improve bone strength and muscle mass in males. However, TRT use has been the subject of some controversy. Continuous testosterone use has been associated with prostate cancer and high red blood cell levels, and its other effects are not fully known.

In one of the first clinical trials involving men over 60-85 years of age, researchers preliminary results indicate that testosterone treatment for five months has a positive effect on the bone markers of older men. This is the first known study to report on the impact of bone metabolism based on dosing schedules.

Presentation at the 121st Annual Meeting of the American Physiological Society

The study was conducted by E. Lichar Dillon, Randall J. Urban, James A. Angel, Shanon L. Casperson and Melinda Sheffield-Moore, all of the Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX; and Douglas Paddon-Jones of the Department of Rehabilitation Sciences and Physical Therapy, the University of Texas Medical Branch. Their study was funded in part by the National Institutes of Health (NIH) and is entitled Continuous Testosterone Administration for Five Months Reduces Markers of Bone Turnover in Older Men. Dr. Dillon is presenting the teams preliminary findings at the 121st Annual Meeting of the American Physiological Society (APS; www.the-APS.org/press), part of the Experimental Biology 2008 scientific conference.

Study Summary

Thirteen older men between 60 85 years have thusfar participated in the study. Testosterone levels ranged between 200-500 nanograms (ng) of testosterone per deciliter of blood (dL) at the time of enrollment. (Normal limits are considered 250-800.) Each was enrolled in one of three double-blinded groups: (1) those receiving continuous weekly intramuscular injections of testosterone (100 mg testosterone-enanthate) for the entire five month period (TE; n=4); (2) those receiving weekly testosterone every other month (one month of weekly testosterone/one month of weekly placebo; MO; n=4); or (3) those receiving a weekly placebo for the entire five month period (PL; n=5).

The participants visited the clinic weekly for either scheduled treatment injections or placebos. Volunteers received a baseline whole-body Dual Energy X-Ray Absorptiometry (DEXA) scan at the beginning and end of the study. Dietary records were obtained and analyzed at month zero, month three and month five. Fasting blood samples were collected at regular intervals throughout the study to examine serum markers of bone metabolism.

The Preliminary Study Results

The research team found that:

  • testosterone administration appears to reduce bone turnover, perhaps closing the gap between resorption and formation

  • thus far, the impact on bone mineral density are unclear but may become more apparent as the study progresses.

  • the effects of testosterone on long-term bone metabolism are unclear, but are expected to have at least a protective effect on existing bone mass over time by preventing unwanted increases in bone turnover that are frequently associated with osteoporosis. Osteoporosis is often associated with high bone turnover (increases in bone resorption as well as in bone formation) which results in decreased BMD.

Conclusions

According to Dr. Dillon, the studys first author, These preliminary data show beneficial effects of testosterone therapy on bone turnover markers in older men with low-to-normal testosterone concentrations using both continuous and monthly cycled testosterone replacement. He added, The effects of sex hormones on markers of bone formation are complex, but this is an important step in understanding how the process works.


'/>"/>

Contact: Donna Krupa
DKrupa@the-aps.org
619-525-6202
American Physiological Society
Source:Eurekalert

Related biology news :

1. Testosterone turns male juncos into blustery hunks -- and bad dads
2. Study finds that even aloof husbands have lower testosterone levels than unmarried men
3. MU researcher links hormone replacement therapy to breast cancer
4. Listen-up ladies: Dont postpone knee-replacement surgery
5. RING finger protein 5 may guide treatment for muscle disease in older adults
6. Stakeholders use science to find common ground on wood supply from forests
7. Worlds largest investor coalition seeks further disclosure on climate change and shareholder value
8. High blood pressure in older adults traced to genes effects in blood vessels
9. Tamiflu effective for treatment and prevention of influenza in children 1 year and older
10. Older climbers face uphill battle on Mount Everest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published ... how a patient who developed lymphedema after being treated for breast cancer benefitted from ... the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
Breaking Biology Technology: